Navigation Links
Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
Date:5/20/2008

DANBURY, Conn., May 20 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Alan Krasner, M.D. has been appointed as the Company's Chief Medical Officer, effective May 27, 2008.

"The addition of Dr. Krasner to our team provides Biodel with strong internal clinical and regulatory leadership and we expect him to play an important role in the clinical development of our product candidates," said Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Dr. Krasner's depth of knowledge in endocrinology and insulin, coupled with his experience developing late stage drug candidates will be valuable in advancing our suite of VIAject(TM) products to market."

Dr. Andreas Pfuetzner, Biodel's current Chief Medical Officer will remain on Biodel's management team as the Company's Chief Medical Officer in Europe and as a member of the Company's Scientific Advisory Board.

"I look forward to working closely with my esteemed colleague to advance VIAject(TM) through the NDA phase of development," said Professor Dr. Andreas Pfuetzner.

Dr. Krasner joins the Company from Pfizer Global Research and Development where he was Director of the Department of Clinical Research Metabolic Diseases and responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner currently serves as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently received a fellowship from Johns Hopkins Hospital in endocrinology and metabolism.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
8. Biodel Inc. Announces Pricing of Public Offering
9. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
10. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
11. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Bulk food product inspection systems are ... stages of the production process. Despite frequently inspecting loose product prior to packaging, ... such as sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper ...
(Date:2/8/2016)... Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), ... Eugene Seymour , MD, MPH, will present information about the company,s ... Hotel in New York City . ... the Windsor Room at 5:30PM EST. Registered attendees can request a ... York City . --> New York ...
(Date:2/8/2016)... announced today that its new website has gone live. On Thursday, Feb. 4, the company unveiled ... Visit the new site: www.diplomat.is ... ... Diplomat Specialty ... "The goal was to reimagine the website and create a smarter, more comprehensive digital ...
(Date:2/6/2016)... ... 2016 , ... The Center for Excellence in Education (CEE) will sponsor a ... Wednesday February 10, 2016. This Bite of Science session, hosted by the Smithsonian-Mason ... 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. The ...
Breaking Biology Technology:
(Date:2/2/2016)... Technology Enhancements Accelerate Growth of X-ray Imaging ... and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth analysis ... as regional market drivers and restraints. The study offers ... market attractiveness, both for digital and computed radiography. Market ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):